The application of iPS cells for diseases in the locomotive system includes the cell therapy using bone or cartilage cells and the understanding of pathogenesis and drug discovery for intractable diseases using patients' derived iPS cells. To promote these researches, the proper knowledge concerning the process from iPS cells to multipotential mesenchymal stromal cell (MSC) and terminally differentiated cells is inevitable. In addition, because there are several different ways to induce terminally differentiation, the biological quality of cells induced by each method should be compared in future.